FDA Accepts Agios’ SNDA for PYRUKYND in Thalassemia Patients
Agios Pharmaceuticals, Inc. announced that the FDA has accepted its supplemental New Drug Application (sNDA) for PYRUKYND® (mitapivat) to treat adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. The application, assigned a Standard review classification, has a Prescription Drug User Fee Act (PDUFA) target date of September 7, 2025.
“Thalassemia is a rare, lifelong inherited blood disorder that causes chronic anemia and severe complications such as organ damage and stroke, with few effective treatment options available today,” said Sarah Gheuens, M.D., P...